Adalimumab for sight-threatening uveitis in Behçet's disease
Authors:
Open Access
- 7 April 2006
- journal article
- case report
- Published by Springer Nature in Eye
- Vol. 21 (6) , 824-825
Abstract
Aims To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. Methods Case note review. Main outcome measure was recurrence of uveitis. Results All patients remained free of recurrence with stable visual acuities. Conclusions Adalimumab appears to maintain disease remission in Behçet's disease.Keywords
This publication has 5 references indexed in Scilit:
- Anti-TNF-α therapy for uveitis: Behçet and beyondEye, 2005
- Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet's disease: An open‐label trialArthritis & Rheumatism, 2005
- A Prospective Trial of Infliximab Therapy for Refractory UveitisArchives of Ophthalmology (1950), 2005
- Infliximab for chronic cystoid macular edema associated with uveitisAmerican Journal of Ophthalmology, 2004
- Effect of infliximab on sight-threatening panuveitis in Behcet's diseaseThe Lancet, 2001